2021
DOI: 10.1182/blood-2021-153937
|View full text |Cite
|
Sign up to set email alerts
|

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)

Abstract: Background: Management of CML with TKIs is constrained by treatment resistance, which portends a poor prognosis particularly in pts failing 2 nd-generation TKIs. Cells with BCR-ABL1 T315I mutations are insensitive to 1 st- and 2 nd -generation TKIs, and compound BCR-ABL1 mutations complicate management with all TKIs (including 3 rd-generation ponatinib). Olverembatinib is a novel, potent, 3 rd-generation, orally active BCR-ABL1 TKI with promising activity against CML , largely irrespective of genotype and has … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 0 publications
0
7
0
Order By: Relevance
“…No bleeding or death developed. The most frequent nonhematologic adverse event was skin hyperpigmentation, hypertriglyceridemia, pyrexia and proteinuria for olverembatinib in the treatment of CML [9,10]. In this study, no patients developed nonhematologic adverse events.…”
Section: Discussionmentioning
confidence: 66%
See 4 more Smart Citations
“…No bleeding or death developed. The most frequent nonhematologic adverse event was skin hyperpigmentation, hypertriglyceridemia, pyrexia and proteinuria for olverembatinib in the treatment of CML [9,10]. In this study, no patients developed nonhematologic adverse events.…”
Section: Discussionmentioning
confidence: 66%
“…Olverembatinib, as a novel third-generation TKI, has shown good efficacy in the treatment of CML with or without the T315I mutation [8][9][10]. However, the efficacy of olverembatinib in newly diagnosed patients with Ph + -ALL is unknown.…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations